Form 4: Catalyst Pharmaceuticals Executive Exercises Stock Options
SEC Form 4 Filing
Steve Miller, Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, exercised stock options for 235,000 shares at $4.01 per share.
Summary
- Steve Miller, the Chief Operating and Scientific Officer of Catalyst Pharmaceuticals, exercised options to purchase 235,000 shares of common stock.
- The exercise price was $4.01 per share.
- This transaction occurred on December 13, 2024.
- Following the transaction, Mr. Miller directly owns 921,996 shares of common stock and 1,552,176 options to purchase common stock.
- The options were granted previously and vested in three annual tranches starting January 2, 2019.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction. It is neither particularly positive nor negative, but the exercise of options by an executive can be seen as a sign of confidence.
Positives
- The exercise of options by a key executive could be seen as a positive sign of confidence in the company's future prospects.
Risks
- The sale of shares acquired through option exercises could potentially put downward pressure on the stock price if a large number of shares are sold.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives exercise stock options. It provides transparency into insider transactions.
Comparison to Industry Standards
- Stock option exercises are a common form of executive compensation in the pharmaceutical industry.
- The vesting schedule of three annual tranches is also a typical practice.
- The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for all publicly traded companies.
Stakeholder Impact
- The transaction may have a minor impact on shareholders, as the exercise of options could potentially lead to an increase in the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 01/02/2019 | Start date for the vesting of the options in three annual tranches. |
| 12/13/2024 | Date of the stock option exercise. |
| 12/17/2024 | Date of the filing of the SEC Form 4. |
| 01/02/2025 | Expiration date of the options. |
Keywords
stock options, insider trading, executive compensation, Catalyst Pharmaceuticals, CPRX, Steve Miller, share ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.